Five-Year Follow-Up of Concomitant Accelerated Hypofractionated Radiation in Advanced Squamous Cell Carcinoma of the Buccal Mucosa: A Retrospective Cohort StudyReport as inadecuate




Five-Year Follow-Up of Concomitant Accelerated Hypofractionated Radiation in Advanced Squamous Cell Carcinoma of the Buccal Mucosa: A Retrospective Cohort Study - Download this document for free, or read online. Document in PDF available to download.

BioMed Research International - Volume 2015 2015, Article ID 963574, 8 pages -

Clinical Study

Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan

Department of Radiation Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan

Aga khan University, Karachi, Pakistan

Lahore Medical and Dental College, Lahore, Pakistan

Received 27 December 2014; Revised 18 April 2015; Accepted 25 April 2015

Academic Editor: Quintin Pan

Copyright © 2015 Hassan Iqbal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

In resource limited settings, induction chemotherapy with Gemcitabine and Cisplatinum and concurrent hypofractionated chemoradiation for locally advanced carcinoma of buccal mucosa BMSCC are a cost effective option but remain under reported. The objective of this study was to report long term survival outcome after concurrent hypofractionated radiotherapy in locally advanced BMSCC. Between February 2005 and 2009, 63 patients received treatment. Induction chemotherapy IC regimen consisted of two drugs: Gemcitabine and Cisplatin. All patients received 55 Gy of radiation in 20 fractions with concurrent single agent Cisplatin 75 mg-m

. Five-year overall survival OS, disease-free survival DFS, and progression-free survival PFS were determined. Based on AJCC staging, 7 11% patients were stage III, 31 49% stage IV a, and 25 40% stage IVb at presentation. After IC, 8 18% patients had complete radiological response, 33 73% had partial response, and 4 9% had stable disease. After concurrent hypofractionated chemoradiation, thirty-nine 62% patients were complete responders and 24 38% had stable disease. With a minimum follow-up of 60 months, 5-year OS, DFS, and PFS were 30%, 49%, and 30%, respectively. In locally advanced buccal mucosa squamous cell carcinoma, concurrent hypofractionated chemoradiation results in acceptable survival and regimen related toxicity.





Author: Hassan Iqbal, Arif Jamshed, Abu Bakar Hafeez Bhatti, Raza Hussain, Sarah Jamshed, Muhammad Irfan, Natasha Hameed, and Adeel

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents